The hypophosphatasia patient community will be well served by the experience and international scope of Alexion. Related StoriesMoffitt Cancer Middle study finds link between common gene mutations and tumor immune surveillanceBerkeley Laboratory scientists identify genetic elements that influence neurological disorders and body weightGenetic reduction of AMPK enzyme can prevent or delay hearing lossThe Deal Alexion will acquire Enobia within an all-cash transaction. Under the terms of the agreement, Alexion has decided to pay out $610 million in money upon consummation of the transaction, and up to $470 million in money to end up being paid upon achievement of varied regulatory and sales milestones.Working with blood samples, the researchers aim to find ways to extract these cells, activate them or gene modify them in sufficient quantities to provide effective treatments. They will seek to identify solutions to accomplish that in a laboratory setting, and then to assess whether they can safely control and manage the produce of the novel cell-based therapies so they can be tested in individuals. By taking this step-by-step approach, they will assess the scientific feasibility of using these ‘enhanced’ cells as therapeutic brokers and put those believed to be most reliable forward for scientific trials. Essential to the success of this programme would be the program of leading-edge cell selection systems and use of new Good Production Practice premises within the Clinical Research Facility at Guy’s Hospital, which is because of open next year, combined with the GMP facility already operating at King’s University Hospital.